ArticlePediatric research2026
Antimicrobial resistance patterns, molecular resistance prediction, and treatment outcomes in pediatric Helicobacter pylori infection.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond accuracy: translating machine learning risk models into meaningful clinical decision support in neonatal intensive care.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance increasingly complicates empirical treatment of pediatric Helicobacter pylori (H. pylori) infection. We examined resistance patterns and the relationship of molecular and culture-based results to treatment and eradication outcomes.
methodsWe retrospectively studied children who underwent clinically indicated endoscopy with paired polymerase chain reaction (PCR) and culture testing between October 2022 and October 2024. Resistance-associated variants were identified by PCR and Sanger sequencing. Culture-positive isolates underwent antimicrobial susceptibility testing, which informed treatment selection. Eradication was assessed by carbon-13 urea breath testing.
resultsOf 145 children, 128 (88.3%) were PCR positive and 92 were culture positive. Phenotypic resistance to clarithromycin (CLA), metronidazole (MTZ), and levofloxacin (LVX) was 82.6%, 81.5%, and 29.3%, respectively; 72.8% of isolates were resistant to at least two antibiotics. Molecular prediction of CLA nonsusceptibility had 98.8% sensitivity, 90.9% specificity, and 97.8% accuracy; corresponding values for LVX were 90.9%, 97.7%, and 95.5%. Eradication was achieved in 86 of 97 treated children (88.7%), and 80 of 84 treated culture-positive children received phenotypically concordant regimens.
conclusionCLA and MTZ resistance and multidrug resistance were frequent. Molecular analysis of 23S rRNA and gyrA complemented culture-based susceptibility testing in treatment selection. IMPACT: Clarithromycin and metronidazole resistance exceeded 80%, and nearly three quarters of the pediatric H. pylori isolates were resistant to at least two antibiotics, substantially limiting empirical treatment options. Molecular analysis of 23S rRNA and gyrA closely reflected phenotypic clarithromycin and levofloxacin nonsusceptibility, whereas molecular findings for other antibiotics were less readily interpretable. By linking molecular and culture-based resistance results with the regimens prescribed and subsequent eradication outcomes, this study shows how the two approaches can complement each other in routine pediatric care.
Identifiers
42693229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.